Skip to main content

Home/ MaRS/ Group items tagged Commercialization

Rss Feed Group items tagged

Assunta Krehl

MaRS Discovery District - News - News Releases - 2009 - Toronto's MaRS Discovery Distri... - 0 views

  • Toronto’s MaRS Discovery District has combined the creative genius of science and technology with the drive of entrepreneurs and capital to create a marriage that will see more Canadian ideas commercialized in this country and for those efforts it has won the Canadian Urban Institute’s 2009 Creative City Award to be granted to MaRS on June 5 at the Urban Leadership Awards in Toronto.
  • “MaRS has found a creative way for science and business to collaborate rather than compete and to help Canada become a knowledge-based economy. This award recognizes them as a leader in stimulating the creative capacity of the city and advancing entrepreneurship, not only in science and technology but also in social ventures. 
  • Located in the Discovery District of Toronto, where billions of dollars of creative capital are created every year, the MaRS Centre first opened in 2005 in two new towers that bookend a heritage building that once housed the Toronto General Hospital. The three buildings, that total 700,000 sq. ft, house labs, companies of all sizes, business advisors and investors. Its professional services include hands-on advisory services, entrepreneurial programming and both structured and electronic networking. A second building phase of the MaRS Centre will add 750,000 sq ft and is planned to open in the next few years. “The underlining reason for creating MaRS is to capture the value of Canadian discoveries and to better commercialize these innovations at home in Canada,” said MaRS CEO Ilse Treurnicht. “Hub cities like Toronto are key drivers in shaping Canada’s innovation economy. MaRS works to strengthen the pull of that hub, acting as an accelerator and building the best ideas into companies that can compete on the world stage but are anchored here,” said Treurnicht.
  •  
    "Mention of the the Canadian Urban Institute's 2009 Creative City Award being granted to MaRS on June 5 at the Urban Leadership Awards in Toronto."
Assunta Krehl

Pharmafocus.com - 0 views

  • Canada has always had to fight hard to attract talent and investment
  • MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.
  • "We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.
  • ...7 more annotations...
  • Transition Therapeutics is one of the companies based at MaRS, and is an example of a biopharmaceutical company that is taking a new approach to the science and business of drug development.
  • Now Toronto's MaRS Innovation (MI) has been launched to try to guide and accelerate these promising ideas out of the wilderness and onto the market. MI is a not-for-profit technology transfer company that will channel all the best ideas to come out of Toronto's renowned academic centres. In the Toronto and Ontario area there were between 14-16 different technology transfer offices in the different institutions, and MaRS Innovation resolved to bring these interests together into a single entity after industry partners told them it was an inefficient way to do business. Bringing together the different institutions under one umbrella organisation has been an arduous task for MaRS, but the reward could be considerable for all parties. MI now oversees probably the largest intellectual property pipeline of its kind, representing about $1 billion in annual research spending. This means MI will be a unified route for all of Toronto's academics and their institutions when they want to develop and commercialise a bright idea. Most importantly, investors from industry who are looking to collaborate will now be able to deal with just organisation and one IP process. MI will cover patentable ideas across a broad range of areas, and not just life sciences - the discovery pipeline in physical sciences, information and communication technology, and green technology ('cleantech') will all be funnelled through MI. MI now represents three universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS Innovation, with support from MaRS and BioDiscovery Toronto, will advance commercialisation through industry partnerships, licensing and company creation.
  • ts chief executive is Dr Rafi Hofstein. Hofstein has been headhunted from Israel where he was chief executive of Hadasit, the technology transfer company of the Hadassah Medical Organization in Jerusalem and chair of the publicly-traded company Hadasit BioHolding. He brings this considerable experience in technology transfer to what he thinks is a groundbreaking enterprise."MaRS Innovation is a unique global initiative, and I must commend the institutional leaders in Toronto for pulling this innovation powerhouse together to strengthen commercialisation output." He adds: "I believe this is going to modernise the whole notion of tech transfer." He says the scale and diversity of MaRS Innovation's remit puts it into a league of its own. Other research clusters elsewhere in the world have attempted similar projects before, but have been thwarted by the difficulty in bringing parties together. MaRS Innovation will also help launch and grow new spin-off companies and incubate them for 2-3 years to ensure a strong commercial footing. Hofstein says MI will also fund proof of concept trials which will persuade major pharma companies to invest in their development.
  • MI has just announced its first two commercialisation deals with academic partners in the city. The first is with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital to develop stem cell from umbilical cords to treat cardiovascular disease, diabetes and neurological disorders. "With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialisation opportunity," said Dr Hofstein.
  • "Our partnership with MaRS Innovation on developing methods for using stem cells for diseases such as diabetes will allow us to work towards advancing care for these critical conditions."
  • The second collaboration is between MI and The University of Toronto (U of T) and involves a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. "There are 300 million diabetics worldwide, of which some 15% develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialisation opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally," said Dr Hofstein.
  • "This is one of many new commercialisation ventures that will be initiated by MaRS Innovation, our partner in commercialisation of research with 13 other academic institutions across the Greater Toronto Area," said Paul Young, U of T's vice-president, Research. "We at U of T are delighted that this innovation from Dr Lee will be taken to the marketplace to the benefit of society and the economy of Ontario and Canada." By aggregating the leading edge science of its institutional members and being a one-stop commercialisation centre for industry, entrepreneurs and investors, MI could really help put Toronto and Canada on the map."MaRS Innovation is deeply committed to facilitating strategic research collaborations with industry partners, strengthening the innovation capacity of Canadian industry through adoption of new technologies, and launching a new generation of robust, high-growth Canadian companies that will become global market leaders," added Dr Hofstein. "We look forward to working closely with all of our institutional members and to continue to jointly announce exciting commercial opportunities."
  •  
    Canada has always had to fight hard to attract talent and investment. As stated in Pharmafocus.com, "MaRS Discovery District helps to foster and accelerate the growth of successful Canadian businesses." MaRS Innovation has also been launched to accelerate ideas onto the market.
Sarah Hickman

The Long Tail: Amazon.ca: Chris Anderson: Books - 0 views

  •  
    The Long Tail is really about the economics of abundance. New efficiencies in distribution, manufacturing, and marketing are essentially resetting the definition of what's commercially viable across the board. If the 20th century was about hits, the 21st will be equally about niches.
Assunta Krehl

reportonbusiness.com: THE COMPANY: INFONAUT INC.: Charting the right course through an ... - 0 views

  • Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.
  • Toronto, where a small firm is using 21st-century software to create maps with similar goals - the containment of disease - by showing infection patterns that can be understood at a glance.
  • There's nothing wrong with Infonaut using the H1N1 flu outbreak to gain exposure, as long as the company is careful in the tone it takes, said John Lute, president of Toronto communications firm Lute and Co.
  • ...15 more annotations...
  • Infonaut Inc. chief executive officer Niall Wallace and his partner, chief operating officer Matt McPherson, both former IT consultants for the Ontario government, created the company after helping to craft some of the recommendations that resulted from the SARS outbreak of 2003. They understood the value of visually represented, real-time infection data, and left government to set up Infonaut to develop that technology.
  • Infonaut has created three software products that turn infection information into maps. All are being tested in pilot projects and will soon be marketed commercially.
  • One, called Infection Watch Live, is now taking data gathered at 14 hospital emergency rooms in eastern Ontario and using it to create publicly accessible maps that show exactly where in the region cases of influenza and gastrointestinal diseases are active.
  • This complex mapping can help monitor and stop the spread of C. difficile and other superbugs.
  • The third product, called Regional Watch Live, generates maps and reports for regional health professionals by merging lab test results with a range of other information.
  • INFONAUT INC
  • Make sure to present straightforward information about how the company's products might help mitigate an outbreak in the future, but do not exaggerate promises. Be upfront about the state of pilot tests, the timelines to get the software to market, and how much funding will be needed to go to full commercialization. Use respected third-party partners to endorse the products, a move that will give the company more credibility. If there are privacy concerns, spell them out and detail how they are being addressed.
  • Infonaut should ensure that its message is understated and that the company is not an "ambulance chaser," Mr. Lute said
  • But the company does need to give straightforward information about how its products might help mitigate an outbreak in the future, and not exaggerate its promises, she said. In particular, it needs to be upfront about the state of its pilot tests and include details of when full versions of its products will be available. It also must explain how much funding they will need to get there, Ms. Wilcox said.
  • With Infonaut, there seems to be no question that there is a public gain, he said. "If it is just an opportunistic attempt to cash in on the misfortune of others, that tends to play badly. Where a company has something that can be tied to the public interest, such as in this case ... it is very low-risk."
  • He suggests that Infonaut make good use of its pilot test partners, such as the counties in eastern Ontario that are testing the Infection Watch Live system.
  • the company should forestall any concerns over privacy issues by spelling out how it ensures data on individuals are kept confidential.
  • There's nothing wrong with using the current concerns over H1N1 flu to gain exposure, as long as Infonaut is careful about taking a calm and respectful tone to its marketing and publicity.
  • On the other hand, it will clearly create an opportunity if Infonaut can increase its profile, "which helps it to get its story out, which helps it to get investors, which helps it to grow.
  • The problem Build a market for a unique infection mapping system without appearing to exploit the flu outbreak The plan: Use a subtle approach and be upfront with the state of development of the software products The payoff: Higher awareness among potential customers and an expanded market
  •  
    Using 21st-century Infonaut is using software to create maps - the containment of disease - by showing infection patterns that can be understood at a glance.
Assunta Krehl

Biomedical research attracting top scientists - City of Toronto - 0 views

  • the Chief of Research at the Hospital for Sick Children in Toronto, collaboration is the key to the future.
  • That's why Dr. Janet Rossant is so enthusiastic about the work being done in the MaRS Discovery District - a unique zone in the city where innovations in science and technology are commercialized through partnerships between researchers and private enterprise.
  • "The MaRS Centre and biomedical community have seen tremendous growth over the past few years," says Dr. Janet Rossant. "And it continues to grow." "This growth is attracting the world's best scientists to come work here, which is very exciting."
  • ...4 more annotations...
  • A key strategic focus of the SickKids Research Institute is the commercialization of research findings-translating discoveries into new technologies and treatments to improve the understanding and treatment of diseases that affect children.
  • "An environment like the Discovery District allows research institutes and the University of Toronto and its affiliated hospitals to work together to promote research and its application," she explains.
  • One of the unique aspects of Toronto is its open, collaborative environment. Individual institutes are not fighting each other for funding resources. This collaborative nature is what people comment on when they come here." A Toronto location provides other advantages too, she says. "There is a strong university and college environment, which provides a great pool from which to draw talent. There is strong support from all three levels of government. And there is strong philanthropic support, which is important." Dr. Rossant says working for the Hospital for Sick Children has been very gratifying.
  • Dr. Rossant is also looking forward to the opening of the new research and education building going up in the Discovery District. "The Research Institute currently has 2,000 people spread across the Discovery District and the new building will bring us all together and allow us to interact in new ways."
  •  
    Dr. Janet Rossant, Chief of Research at The Hospital for Sick Children says they key to the future is "collaboration." Rossant is enthusiastic about the work being done at MaRS.
  •  
    Dr. Janet Rossant, Chief of Research at The Hospital for Sick Children says they key to the future is "collaboration." Rossant is enthusiastic about the work being done at MaRS. Jan 19, 2009
George Botos

News: Transition Therapeutics and Lilly Expand Diabetes Partnership through Licensing o... - 0 views

  •  
    Eli Lilly will earn $1 million up front as part of a licensing deal for a series of its preclinical diabetes compounds with Transition Therapeutics.The agreement gives Transition exclusive, worldwide rights to develop and commercialize the compounds.
Assunta Krehl

The 2010 Annual International Conference on Research Facilities - PRNewswire - March 2,... - 0 views

  •  
    On May 17 & 18 the 2010 Annual International Conference on Research Facilities will be held in Toronto. The major issues on the agenda include getting more research results per square foot of space, lowering the costs of building and renovating research facilities, reducing facility operating costs, facilitating the new collaborative multi-disciplinary research models, planning facilities help to promote commercial technology spin-offs, and designing energy-efficient and sustainable laboratories.An important feature of the conference is the opportunity for participants to tour a number of prominent Toronto research facilities including MaRS Discovery District.
Assunta Krehl

* Printer friendly version * Email story to a friend * Send your comments to th... - 1 views

  •  
    MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries. Dec 15, 2009
Assunta Krehl

Lab Canada - * Printer friendly version * Email story to a friend * Send ... - 0 views

  •  
    To improve early detection and treatment of cancer, a pair of Toronto scientists, Dr David Jaffray, a senior scientist in the division of biophysics and bioimaging at the Ontario Cancer Institute and Dr Christine Allen, an associate professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto has developed a technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Dec 23, 2009
Assunta Krehl

Automate to Market - The Scientist - January 2010 - 1 views

  •  
    The Scientist spoke with researchers who are automating and commercializing the latest technologies to aid life science work. Ameer Taha, founder, Certo Labs, Toronto and Veronika Litinski, health-care and life sciences practice lead at the MaRS Centre, a Toronto-based innovation cluster that engages researchers in commercializing their inventions were interviewed. Litinski states that "Before people start spending money on [developing] a product, we want them to think about the value chain and how the industry ecosystem is organized."
Assunta Krehl

Physician melds research and entrepreneurship - The Globe and Mail - April 9, 2010 - 0 views

  •  
    Carly Weeks, a Globe and Mail reporter interviews Dr. Calvin Stiller. "Dr. Stiller was named a recipient of a prestigious Canada Gairdner Award and always had a dire need to fix the imbalance of research and commercial development in the country's life sciences. He says he has always had an entrepreneurial spirit, which inspired him to work with colleagues to create centres such as the Toronto-based MaRS Discovery District."
Assunta Krehl

Canadian Digital Media Network Welcomes MaRS As New Node on Cross-Canada Network - Dail... - 0 views

  •  
    MaRS Discovery District is the newest addition to the Canadian Digital Media Network (CDMN). The collaboration will enhance levels of technology commercialization and help develop successful companies in the digital media sector.
Cathy Bogaart

Toronto's 1DegreeBio brings open source innovation to biological research industry - Yo... - 0 views

  •  
    Minister Glen Murray (Ministry of Research and Innovation) launched MaRS as a member of the Ontario Network of Excellence last month. In his speech, he highlighted our client, 1DegreeBio. 1DegreeBio helps those in the biological sciences share their data, including being th first online independent resource listing all academic and commercially available antibodies. Score 1 for open science!
Assunta Krehl

Research improves performance of next-generation solar cell technology - Physorg - Sept... - 0 views

  •  
    As stated in the Psych org "Researchers from the University of Toronto (U of T), the King Abdullah University of Science & Technology (KAUST) and Pennsylvania State University (Penn State) have created the most efficient solar cell ever made based on collodial-quatum-dots...a technology licensing agreement has been signed by U of T and KAUST, brokered by MaRS Innovations (MI), which will will enable the global commercialization of this new technology." 
Assunta Krehl

U of T-led research improves performance of next-generation solar cell technology - Sci... - 0 views

  •  
    As stated in the Science Daily "Researchers from the University of Toronto (U of T), the King Abdullah University of Science & Technology (KAUST) and Pennsylvania State University (Penn State) have created the most efficient solar cell ever made based on collodial-quatum-dots...a technology licensing agreement has been signed by U of T and KAUST, brokered by MaRS Innovations (MI), which will will enable the global commercialization of this new technology." 
Assunta Krehl

Physicist pairs with pharmaceutical scientist to design nano-particles for cancer imagi... - 0 views

  •  
    A pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Nov 20, 2009
Assunta Krehl

Physicist pairs with pharmaceutical scientist to design nano-particles for cancer imagi... - 0 views

  •  
    A pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Nov 19, 2009
Assunta Krehl

MaRS Innovation and CDRD Announce Strategic Collaboration - Canada Newswire - 0 views

  •  
    "MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries." Nov 30, 2009
Miri Katz

Globe and Mail: Time for action on innovation, not more study - 0 views

  • Time for action on innovation, not more study By BARRIE McKENNA From Monday's Globe and Mail If more recommendations from important 2008 federal report Compete to Win had been implemented, Ottawa might not still be talking about innovation deficiencies
  • If innovation was measured in the output of reports about innovation, Canada would be a world leader.We're not. We are a laggard. The report tracked Canada's progress over the past two years based on 24 different indicators, such as the percentage of GDP spent on research and development, R&D spending by businesses, investment in machinery and equipment, PhDs and high school test scores. Since the council's initial report in 2008, Canada's performance is down in 15 categories, stagnant in three and improved in just six.
  • Here's a passage from L.R. (Red) Wilson's seminal 2008 federal report, Compete to Win: "We rank poorly across almost all aspects of innovation: the creation of knowledge, the diffusion of knowledge, the transformation of knowledge and the use of knowledge through commercialization."
  • ...4 more annotations...
  • The R&D focus should be on industry clusters that can leverage the country's natural resource wealth and traditional strengths. Think energy, water, agriculture, forestry, mining and manufacturing that serves vital Canadian needs.
  • In areas most closely linked to innovation, the progress is equally slow. Mr. Wilson, for example, urged Ottawa to look at creating tax incentives to encourage venture capital and speeding up the commercialization of intellectual property developed in universities.
  • The to-do list on the path achieving that objective is long. There's overhauling the Investment Canada and Competition acts, opening up the telecom and broadcast industries to more foreign competition, creating a national securities regulator, reforming copyright laws, eliminating remaining internal trade barriers and lowering personal income tax rates.
  • It may mean that government plays a larger role in some industries while leaving others to their own devices. That, at least, is how other similarly sized economies successfully leverage limited government funds.More study has become an excuse to put off these much tougher, but inevitable, choices.
« First ‹ Previous 81 - 100 of 150 Next › Last »
Showing 20 items per page